Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Serum Institute of India Pvt. Ltd.
With
University of Colorado, Boulder
Centers for Disease Control and Prevention
This is a phase I, open-label, randomized study in healthy adults. Eligible subjects will be given single dose of either Dry Powdered Measles Vaccine (PMV) by Puffhaler® device, Dry PMV by SoloventTM device or licensed measles vaccine by subcutaneous route (SMV). Solicited reactions will be assessed for first 14 days after vaccination and unsolicited adverse events will be assessed till 84 days after vaccination. Subjects will be followed for 180 days for any SAEs.
Age
18–45
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Male adults of age of 18-45 years.
Measles immune, as determined by IgG antibody levels.
Healthy as supported by medical history, physical examination and laboratory evaluation on preset parameters.
Signed informed consent for participation in trial and for HIV screening.
You may not be if
Medical history of immunodeficiency/suppression or subject with history of close contact with immunocompromised/ immunosuppressed person.
Chronic administration of immunosuppressants or other immune modifying agents
Acute febrile illness or suspected measles illness or acute infectious disease
Acute or chronic, clinically significant pulmonary, endocrine, autoimmune, psychiatric, cardiovascular, neurological, hepatic or renal functional abnormality which in the opinion of the investigator, might interfere with the study objectives
History of seizure disorders
Major congenital defects
Thrombocytopenia or known bleeding disorders 8. History of a previous severe allergic reaction
Positive serology for HIV antibody, HCV antibody or Hepatitis B surface antigen
Known hypersensitivity to any component of the study vaccine